An association between infantile haemangiomas and erythropoietin treatment in preterm infants

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 97, Issue 1, 2012, Pages

  Doege, Corinna ^a   Pritsch, Maria ^a   Frühwald, Michael C ^b   Bauer, Jacqueline ^b,c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; CAPILLARY HEMANGIOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GESTATIONAL AGE; HUMAN; INCIDENCE; INDEPENDENT VARIABLE; INFANT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OXYGEN THERAPY; PREMATURITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE;

BIRTH WEIGHT; ERYTHROPOIETIN; FEMALE; GERMANY; GESTATIONAL AGE; HEMANGIOMA; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; MALE; PREVALENCE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 84455188353     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2010.187344     Document Type: Article

References (35)

1. Kilcline C, Frieden IJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol 2008;25:168-73. (Pubitemid 351579596)
2. Chiller KG, Passaro D, Frieden IJ. Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol 2002;138:1567-76. (Pubitemid 35453469)
3. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med 1999;341:173-81. (Pubitemid 29325746)
4. Takahashi K, Mulliken JB, Kozakewich HP, et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994;93:2357-64. (Pubitemid 24177146)
5. Phung TL, Hochman M, Mihm MC. Current knowledge of the pathogenesis of infantile hemangiomas. Arch Facial Plast Surg 2005;7:319-21. (Pubitemid 43973816)
6. Mulliken JB. Diagnosis and natural history of hemangiomas. In: Mulliken JB, Young AE, eds. Vascular Birthmarks: Hemangiomas and Malformations. Philadelphia, PA: WB Saunders 1988:41-62.
7. Burton BK, Schulz CJ, Angle B, et al. An increased incidence of haemangiomas in infants born following chorionic villus sampling (CVS). Prenat Diagn 1995;15:209-14.
8. Amir J, Metzker A, Krikler R, et al. Strawberry hemangioma in preterm infants. Pediatr Dermatol 1986;3:331-2. (Pubitemid 17199330)
9. Powell TG, West CR, Pharoah PO, et al. Epidemiology of strawberry haemangioma in low birthweight infants. Br J Dermatol 1987;116:635-41. (Pubitemid 17064643)
10. Drolet BA, Swanson EA, Frieden IJ; Hemangioma Investigator Group. Infantile hemangiomas: an emerging health issue linked to an increased rate of low birth weight infants. J Pediatr 2008;153:712-5, 715.e1.
11. Zaffanello M, Franchini M, Rugolotto S. Recombinant human erythropoietin might induce strawberry haemangiomas in very-low-birthweight preterm infants. Acta Paediatr 2003;92:1353-4. (Pubitemid 37465186)
12. Leung SP. Multiple strawberry haemangiomas-side effect of rhuEpo? Acta Paediatr 2000;89:890. (Pubitemid 30622596)
13. Ohls RK. Human recombinant erythropoietin in the prevention and treatment of anemia of prematurity. Paediatr Drugs 2002;4:111-21. (Pubitemid 34261180)
14. Crivellato E, Nico B, Vacca A, et al. Recombinant human erythropoietin induces intussusceptive microvascular growth in vivo. Leukemia 2004;18:331-6. (Pubitemid 38240050)
15. Müller-Ehmsen J, Schmidt A, Krausgrill B, et al. Role of erythropoietin for angiogenesis and vasculogenesis: from embryonic development through adulthood. Am J Physiol Heart Circ Physiol 2006;290:H331-40.
16. Hesse V, Voigt M, Sälzler A, et al. Alterations in height, weight, and body mass index of newborns, children, and young adults in eastern Germany after German reunification. J Pediatr 2003;142:259-62. (Pubitemid 36338007)
17. Grambsch PM, Therneau TM. Testing proportional hazards. In: Therneau TM, Grambsch PM (eds). Modeling survival In: Modeling survival data: Extending the Cox Model. New York, NY: Springer 2000:127-52.
18. Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 2007;150:291-4. (Pubitemid 46328964)
19. North PE, Waner M, Mizeracki A, et al. A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol 2001;137:559-70. (Pubitemid 32458438)
20. Barnés CM, Huang S, Kaipainen A, et al. Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Natl Acad Sci USA 2005;102:19097-102. (Pubitemid 43049572)
21. Praveen V, Vidavalur R, Rosenkrantz TS, et al. Infantile hemangiomas and retinopathy of prematurity: possible association. Pediatrics 2009;123:e484-9.
22. Shannon KM, Mentzer WC, Abels RI, et al. Recombinant human erythropoietin in the anemia of prematurity: results of a placebo-controlled pilot study. J Pediatr 1991;118:949-55.
23. Ohlsson A, Aher SM. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006;3:CD004863.
24. Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2006;3:CD004865.
25. Junk AK, Mammis A, Savitz SI, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci USA 2002;99:10659-64.
26. Juul SE, McPherson RJ, Bauer LA, et al. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics 2008;122:383-91.
27. Fauchère JC, Dame C, Vonthein R, et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics 2008;122:375-82.
28. Kleinman ME, Greives MR, Churgin SS, et al. Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arterioscler Thromb Vasc Biol 2007;27:2664-70. (Pubitemid 350158920)
29. Ribatti D, Vacca A, Roccaro AM, et al. Erythropoietin as an angiogenic factor. Eur J Clin Invest 2003;33:891-6. (Pubitemid 37215045)
30. Hardee ME, Kirkpatrick JP, Shan S, et al. Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Br J Cancer 2005;93:1350-5. (Pubitemid 41752861)
31. Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 2007;356:2445-8. (Pubitemid 46919767)
32. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60. (Pubitemid 37324251)
33. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24. (Pubitemid 351397066)
34. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132-49.
35. Batra S, Perelman N, Luck LR, et al. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003;83:1477-87. (Pubitemid 37267831)